CRISPR Therapeutics Stock Target Price and Analyst Consensus

CRSP
 Stock
  

USD 77.46  1.41  1.79%   

The current analyst and expert consensus on CRISPR Therapeutics is Buy, with 1 strong sell and 12 strong buy opinions. The current projected CRISPR Therapeutics target price consensus is 160.69 with 13 analyst opinions. The most common way CRISPR Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview CRISPR Therapeutics executives and customers to further validate their buy or sell advice. CRISPR Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected CRISPR Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 29.558. Continue to Macroaxis Advice on CRISPR Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
As of 11th of August 2022, Gross Profit is likely to grow to about 987.2 M. Also, Profit Margin is likely to grow to 0.51. CRISPR Therapeutics Shareholders Equity is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Shareholders Equity of 2.4 Billion. As of 11th of August 2022, Goodwill and Intangible Assets is likely to grow to about 128.3 K, while Accumulated Retained Earnings Deficit are likely to drop (211.4 M).

CRISPR Therapeutics Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CRISPR target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts performance other than comparing it to the past results via a very sophisticated attribution analysis. CRISPR target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
Number of Opinions16
Lowered Outlook0
Raized Outlook0
Buy
Most CRISPR analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CRISPR stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CRISPR Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

CRISPR Therapeutics Target Price Projection

CRISPR Therapeutics' current and average target prices are 77.46 and 160.69, respectively. The current price of CRISPR Therapeutics is the price at which CRISPR Therapeutics AG is currently trading. On the other hand, CRISPR Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

CRISPR Therapeutics Market Quote on 11th of August 2022

Low Price77.27Odds
High Price83.74Odds

77.46

Target Price

Analyst Consensus On CRISPR Therapeutics Target Price

Low Estimate100.0Odds
High Estimate220.0Odds
Number of Analysts13
Standard Deviation29.558

160.692

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on CRISPR Therapeutics AG and the information provided on this page.

CRISPR Therapeutics Analyst Ratings

CRISPR Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about CRISPR Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of CRISPR Therapeutics' financials, market performance, and future outlook by experienced professionals. CRISPR Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About CRISPR Therapeutics Target Price Projections

CRISPR Therapeutics's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as CRISPR Therapeutics and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of CRISPR depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for CRISPR Therapeutics AG including analysis of its current option contracts.
CRISPR Therapeutics' latest option contracts expiring on 2022-08-12 are carrying combined implied volatility of 120.16 with a put-to-call open interest ratio of 0.39 over 130 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2022-08-12. The current put volume is at 318, with calls trading at the volume of 1497. This yields a 0.21 put-to-call volume ratio. The CRISPR Therapeutics option chain provides detailed quote and price information for the current CRISPR Therapeutics AG option contracts. It shows all of CRISPR Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2022-08-12 Option Contracts

CRISPR Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in CRISPR Therapeutics' lending market. For example, when CRISPR Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on CRISPR Therapeutics, he or she must hedge the risk by shorting CRISPR Therapeutics stock over its option's life.
The chart above shows CRISPR Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. CRISPR Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for CRISPR Therapeutics' option, there is no secondary market available for investors to trade.

CRISPR Therapeutics Maximum Pain Price across 2022-08-12 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as CRISPR Therapeutics close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
CRISPR Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of CRISPR Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell CRISPR stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If CRISPR Therapeutics' stock price goes up or down, the stock options follow.
Continue to Macroaxis Advice on CRISPR Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

CRISPR Therapeutics In The Money Call Balance

When CRISPR Therapeutics' strike price is surpassing the current stock price, the option contract against CRISPR Therapeutics AG stock is said to be in the money. When it comes to buying CRISPR Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on CRISPR Therapeutics AG are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

CRISPR Current Options Market Mood

CRISPR Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps CRISPR Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of CRISPR Therapeutics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. CRISPR Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current CRISPR Therapeutics' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional CRISPR Therapeutics Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of CRISPR Therapeutics is a key component of CRISPR Therapeutics valuation and have some predictive power on the future returns of a CRISPR Therapeutics.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
76.3181.2386.15
Details
Intrinsic
Valuation
LowReal ValueHigh
69.7197.28102.20
Details
Naive
Forecast
LowNext ValueHigh
72.8777.7982.70
Details
Earnings
Estimates (10)
LowProjected EPSHigh
4.765.005.29
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.

Additional CRISPR Therapeutics Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of CRISPR Therapeutics is a key component of CRISPR Therapeutics valuation and have some predictive power on the future returns of a CRISPR Therapeutics.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
76.3181.2386.15
Details
Intrinsic
Valuation
LowReal ValueHigh
69.7197.28102.20
Details
Naive
Forecast
LowNext ValueHigh
72.8777.7982.70
Details
Earnings
Estimates (10)
LowProjected EPSHigh
4.765.005.29
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Momentum
Invested over 20 shares
Driverless Cars
Invested over 70 shares
Macroaxis Index
Invested few shares
Continue to Macroaxis Advice on CRISPR Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
The data published in CRISPR Therapeutics' official financial statements usually reflect CRISPR Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CRISPR Therapeutics. For example, before you start analyzing numbers published by CRISPR accountants, it's critical to develop an understanding of what CRISPR Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of CRISPR Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CRISPR Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CRISPR Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CRISPR Therapeutics AG. Please utilize our Beneish M Score to check the likelihood of CRISPR Therapeutics' management to manipulate its earnings.